Form 8-K ARVINAS, INC. For: Sep 28

September 28, 2021 7:31 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Slide 1

Rapid pace of anticipated milestones ARV-110 (AR PROTAC®) Initiate abiraterone combination study Share complete Phase 1 dose escalation and interim ARDENT Phase 2 data (anticipated at ASCO GU) Share completed ARDENT Phase 2 data Share interim abiraterone combination data ARV-766 (AR PROTAC®) Initiate Phase 1 Share Phase 1 data Initiate Phase 2 INDs ARV-766 BCL6 Tau Undisclosed oncology ARV-471 (ER PROTAC®) Share completed Phase 1 data (anticipated at SABCS) Initiate Phase 1b combination study with everolimus Begin early breast cancer study (neoadjuvant setting) Initiate Phase 3 studies in metastatic breast cancer (as monotherapy and in combination) VERITAC Phase 2 data Safety data from Phase 1b IBRANCE® (palbociclib) combination study data 2021 2022 INDs Four additional INDs through 2023 Exhibit 99.1

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

SEC Filings